Biocon Ltd.

NSE: BIOCON · Healthcare

₹365.10+0.86%06 Nov 2026

Ask the data

Instant answers about Biocon Ltd. — computed from its filings, no language model

Market cap₹59,497 cr

Current price₹365.10

High / Low₹441 / ₹324

P/E131.6

P/B1.71

Book value₹213.8

ROE1.3%

ROCE2.5%

Debt / equity0.43

Dividend yield0.15%

EPS (TTM)₹2.77

Face value₹5

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 8 periods

	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	5,514	6,367	7,106	8,184	11,174	14,756	15,262	16,927
EBITDA	1,394	1,603	1,653	1,970	2,512	3,299	3,166	3,455
Operating margin	25.3%	25.2%	23.3%	24.1%	22.5%	22.4%	20.7%	20.4%
Interest	71	65	58	68	419	974	897	990
Depreciation	448	552	715	814	1,113	1,569	1,687	1,957
Profit before tax	1,214	1,215	1,147	1,190	1,064	1,609	1,887	448
Tax	212	315	222	212	254	227	457	79
Net profit	905	748	740	648	463	1,022	1,013	386
EPS ₹	15.30	6.32	6.24	5.44	3.88	8.55	8.46	2.82
Operating cash flow	—	—	—	1,177	1,852	2,954	4,061	1,994
Capex	—	—	—	1,925	1,726	1,932	2,343	1,912
Dividend paid	—	—	—	-346	72	203	83	91
Total assets	12,192	14,444	18,522	20,394	52,043	56,071	58,797	63,651
Equity	6,098	6,706	7,627	8,432	17,867	19,784	21,644	34,032

Quarterly performance

last 33 quarters · ₹ crore

showing latest 8 of 33 periods

	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	1,321	1,541	1,529	1,466	1,572	1,748	1,581	1,671	1,745	1,851	1,839	1,761	1,840	2,174	2,409	2,140	2,320	2,941	3,774	3,423	3,462	3,954	3,917	3,433	3,590	3,821	4,417	3,942	4,296	4,173	4,517	4,336	4,389
Operating profit	340	381	403	438	403	444	319	413	391	400	436	389	446	488	592	399	471	644	997	714	742	927	916	620	685	752	1,078	749	835	834	1,020	847	831
Operating margin	25.7%	24.7%	26.4%	29.8%	25.6%	25.4%	20.2%	24.7%	22.4%	21.6%	23.7%	22.1%	24.2%	22.5%	24.6%	18.7%	20.3%	21.9%	26.4%	20.9%	21.4%	23.4%	23.4%	18.1%	19.1%	19.7%	24.4%	19.0%	19.4%	20.0%	22.6%	19.5%	18.9%
Other income	54	26	28	24	38	36	63	18	16	28	205	47	105	48	67	78	64	79	155	94	158	566	49	1,134	32	35	37	80	93	117	52	54	34
Interest	19	19	16	17	14	18	17	12	6	5	34	20	22	15	10	20	30	120	249	233	248	267	227	236	226	223	212	277	272	210	232	213	240
Depreciation	112	117	120	124	132	144	152	167	178	186	184	195	202	206	212	218	231	301	364	358	389	414	407	405	420	425	436	455	473	515	513	547	564
Profit before tax	452	277	296	321	363	318	212	252	223	236	436	222	257	316	396	240	257	30	537	217	238	832	322	1,146	98	156	487	97	171	-68	248	128	55
Tax	73	46	41	85	100	85	45	81	22	49	69	57	46	49	59	30	147	-5	82	35	42	55	96	284	71	75	27	8	38	-16	49	-9	-2
Net profit	355	217	214	206	216	203	123	168	169	169	253	108	138	187	239	144	47	-42	313	101	126	660	136	660	-16	25	344	31	84	144	126	141	41
EPS ₹	6.00	3.67	3.61	1.74	1.82	1.71	1.04	1.26	1.43	1.42	2.13	0.71	1.16	1.57	2.00	1.21	0.39	-0.35	2.62	0.85	1.05	5.52	1.13	5.51	-0.13	0.21	2.88	0.26	0.66	1.08	0.79	0.87	0.25
Revenue YoY	—	—	—	—	19.0%	13.5%	3.4%	14.0%	11.0%	5.9%	16.3%	5.3%	5.5%	17.5%	31.0%	21.5%	26.0%	35.3%	56.7%	60.0%	49.3%	34.4%	3.8%	0.3%	3.7%	-3.3%	12.8%	14.8%	19.6%	9.2%	2.3%	10.0%	2.2%
Profit YoY	—	—	—	—	-39.2%	-6.6%	-42.3%	-18.7%	-21.5%	-16.9%	105.2%	-35.4%	-18.3%	11.0%	-5.8%	33.2%	-66.1%	-122.3%	31.3%	-29.8%	167.8%	—	-56.7%	550.6%	-112.7%	-96.2%	154.2%	-95.2%	—	472.9%	-63.5%	349.4%	-51.1%

Earlier results (standalone, Sep '07 – Jun '18)

₹ crore · from BSE, before the NSE XBRL filings begin

Biocon Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 10 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†	FY18†
Revenue	926	1,199	1,567	1,559	1,938	2,198	2,242	2,324	2,609	2,426
Operating profit	223	328	584	364	398	460	424	439	588	303
Operating margin	24.1%	27.3%	37.3%	23.3%	20.5%	20.9%	18.9%	18.9%	22.5%	12.5%
Other income	61	30	26	37	60	70	155	184	102	140
Interest	5	2	2	3	1	1	1	1	4	1
Depreciation	74	80	90	94	95	122	128	131	151	136
Profit before tax	205	276	517	304	347	407	428	1,014	536	306
Tax	93	28	58	49	71	78	67	206	17	67
Net profit	112	248	459	256	276	329	361	809	519	238

Quarters

showing latest 8 of 44 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†
Revenue	236	194	220	221	250	225	230	252	301	310	336	332	345	510	380	348	392	386	433	447	508	507	476	541	559	526	571	559	567	533	583	591	558	533	641	696	626	655	632	581	605	592	648	672
Operating profit	60	39	68	44	55	65	60	67	77	87	96	98	115	256	116	87	100	90	87	84	128	107	78	110	129	99	122	116	123	82	103	132	107	85	116	179	132	153	124	86	73	56	88	82
Operating margin	25.5%	20.2%	30.7%	19.9%	21.9%	28.6%	26.1%	26.8%	25.7%	28.0%	28.7%	29.5%	33.2%	50.2%	30.4%	24.9%	25.5%	23.2%	20.2%	18.8%	25.3%	21.1%	16.4%	20.2%	23.1%	18.8%	21.4%	20.8%	21.7%	15.4%	17.6%	22.3%	19.1%	15.9%	18.0%	25.8%	21.1%	23.4%	19.6%	14.8%	12.1%	9.4%	13.6%	12.2%
Other income	6	25	17	16	19	16	10	7	11	6	6	6	6	6	8	8	8	10	10	22	10	20	9	28	20	11	11	12	115	15	14	33	40	32	78	29	26	33	14	26	46	37	31	40
Interest	1	0	1	2	2	1	1	1	0	0	1	1	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	0	0	—
Depreciation	17	17	17	18	18	19	19	20	20	20	20	21	22	23	24	23	23	23	24	24	23	24	24	27	30	31	34	31	32	33	32	32	32	33	33	36	38	38	38	37	33	33	32	32
Profit before tax	47	47	66	41	53	61	50	54	69	72	81	82	98	238	98	71	84	76	73	81	115	103	48	110	119	78	99	97	205	64	62	133	628	84	170	172	118	147	99	74	85	60	87	255
Tax	3	-237	4	11	20	37	26	7	6	7	9	10	11	27	10	11	16	11	10	13	26	22	10	24	23	18	12	22	23	7	15	30	129	15	32	30	48	43	-105	20	17	16	15	25
Net profit	44	284	62	30	34	24	24	48	62	66	73	72	87	212	88	60	68	65	62	69	88	80	38	86	95	60	87	75	182	57	48	103	499	68	138	141	70	104	204	54	68	44	72	230
EPS ₹	4.55	29.39	6.42	3.10	1.74	1.25	1.25	2.46	3.23	3.39	3.72	3.72	4.47	10.81	4.50	3.09	3.48	3.31	3.18	3.52	4.51	4.10	1.95	4.41	4.87	3.06	4.42	3.80	9.25	2.92	2.39	5.17	24.93	3.43	6.91	7.21	3.57	5.30	10.37	0.92	1.16	0.74	1.22	3.89
Revenue YoY	—	—	—	—	6.0%	16.1%	4.5%	13.7%	20.6%	37.4%	46.3%	32.1%	14.5%	64.6%	12.9%	4.7%	13.8%	-24.3%	14.0%	28.6%	29.6%	31.2%	10.0%	20.9%	10.1%	3.9%	20.1%	3.3%	1.3%	1.2%	2.1%	5.8%	-1.5%	0.1%	9.9%	17.7%	12.1%	22.9%	-1.4%	-16.6%	-3.4%	-9.6%	2.5%	15.8%
Profit YoY	—	—	—	—	-23.8%	-91.5%	-61.1%	58.4%	86.0%	173.3%	200.9%	52.1%	40.0%	221.6%	21.2%	-16.5%	-22.1%	-69.4%	-29.2%	14.0%	29.8%	23.9%	-38.6%	25.6%	8.0%	-25.2%	126.5%	-13.7%	90.2%	-4.5%	-44.9%	38.6%	174.7%	19.6%	189.2%	36.7%	-86.0%	52.0%	47.5%	-61.5%	-2.3%	-58.0%	-64.7%	321.5%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 30 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	16.3%	14.0%	13.8%	11.2%	10.6%	9.9%	9.4%	10.0%	9.2%	8.8%	9.0%	8.0%	8.4%	6.4%	4.0%	2.6%	2.3%	2.6%	6.3%	5.2%	8.0%	6.9%	3.8%	4.7%	1.8%	1.8%	2.3%	1.1%	1.5%	1.3%
ROCE	17.9%	16.8%	17.3%	14.9%	14.0%	12.3%	11.2%	10.1%	9.9%	10.3%	11.0%	9.4%	9.6%	8.4%	7.2%	4.2%	4.7%	5.1%	7.7%	7.3%	9.9%	9.0%	7.1%	7.1%	4.5%	4.4%	3.9%	2.9%	2.9%	2.5%
Net margin	16.9%	14.0%	13.3%	11.8%	10.8%	9.8%	9.2%	10.7%	9.7%	9.2%	9.0%	8.2%	8.3%	6.8%	4.0%	4.1%	3.4%	3.7%	8.2%	6.9%	10.7%	9.7%	5.4%	6.6%	2.4%	2.9%	3.6%	2.3%	2.9%	2.6%
EBITDA margin	26.7%	26.6%	26.7%	25.2%	24.0%	23.2%	22.2%	23.1%	22.5%	22.9%	23.1%	23.4%	22.5%	21.6%	21.5%	22.5%	22.7%	22.8%	23.1%	22.4%	21.7%	21.1%	20.1%	20.5%	20.7%	20.7%	20.8%	20.3%	20.4%	20.3%
Debt / equity	0.29	0.29	0.29	0.28	0.28	0.28	0.28	0.57	0.57	0.57	0.57	0.58	0.58	0.58	0.58	0.99	0.99	0.94	0.94	0.80	0.80	0.77	0.77	0.82	0.82	0.59	0.59	0.44	0.44	0.43
Interest coverage	20.24	20.36	21.28	19.72	19.86	19.80	23.75	20.88	18.15	15.18	14.52	18.60	18.87	17.10	6.11	3.54	2.65	2.20	2.83	2.65	3.60	3.51	2.89	3.10	1.89	1.93	1.71	1.45	1.52	1.40
Asset turnover	0.48	0.50	0.52	0.44	0.46	0.47	0.47	0.38	0.39	0.39	0.41	0.40	0.42	0.40	0.43	0.21	0.24	0.25	0.27	0.26	0.26	0.26	0.26	0.26	0.27	0.26	0.27	0.27	0.27	0.27

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 18 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	100	100	100	100	300	300	600	600	600	600	600	600	600	600	600	668	810	815
Other equity / reserves	2,844	2,998	3,934	4,738	4,881	5,798	6,106	7,027	7,832	9,028	17,267	18,382	19,183	20,393	21,044	26,135	33,221	34,028
Total equity	2,944	3,098	4,034	4,838	5,181	6,098	6,706	7,627	8,432	9,628	17,867	18,982	19,784	20,993	21,644	26,804	34,032	34,843
Borrowings	850	1,031	2,467	2,205	1,920	1,787	1,890	4,359	4,904	5,615	17,771	17,824	15,730	16,150	17,756	15,908	14,825	15,110
Current liabilities	1,380	1,555	1,666	1,678	2,141	3,038	4,008	4,210	3,828	4,125	8,511	10,366	15,359	15,805	14,334	16,254	14,069	14,731
Non-current liabilities	1,262	1,378	2,493	2,502	2,200	2,447	3,053	5,805	7,096	7,699	21,043	19,933	15,437	14,603	16,751	13,450	12,960	13,393
Total assets	5,751	6,375	8,458	9,394	9,990	12,192	14,444	18,522	20,394	22,664	52,043	54,577	56,071	57,128	58,797	62,760	63,651	65,280
Property, plant & equipment	1,504	1,581	1,681	3,553	3,630	4,253	5,393	5,557	5,677	7,171	7,535	7,662	7,418	7,462	8,708	8,865	9,473	9,766
Capital work-in-progress	1,083	1,494	2,060	533	779	1,287	1,576	2,254	3,420	2,275	2,588	3,260	3,985	4,354	4,102	4,651	4,613	4,568
Investments	765	230	875	1,211	611	969	952	1,772	1,580	2,853	2,069	2,040	1,000	1,809	1,127	2,426	1,779	1,324
Inventories	377	453	542	635	722	1,032	1,436	1,867	2,298	2,982	4,244	4,911	4,944	4,965	4,931	5,777	6,086	7,145
Receivables	600	770	714	883	1,064	1,292	1,224	1,503	2,058	2,079	3,573	4,033	6,231	6,129	5,488	5,519	5,987	6,059
Cash & equivalents	804	938	761	710	501	730	910	953	663	751	1,324	644	1,234	1,688	3,227	4,275	2,416	2,204

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 13 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	561	211	371	640	662	1,155	1,283	1,160	1,177	1,852	2,954	4,061	1,994
Cash from investing	-938	-509	-1,142	-498	-684	-714	-1,559	-3,625	-1,699	-14,282	-1,004	-234	-2,082
Cash from financing	426	186	1,068	-178	-240	-242	388	2,564	242	13,049	-2,333	-1,854	-924
Capex	10	79	804	762	738	1,222	1,604	1,517	1,925	1,726	1,932	2,343	1,912
Free cash flow	551	132	-433	-122	-76	-68	-321	-357	-748	126	1,022	1,718	82
Dividends paid	150	125	220	0	79	79	70	—	-346	72	203	83	91

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹9,766 cr15%

CWIP

₹4,568 cr7%

Investments

₹1,324 cr2%

Inventories

₹7,145 cr11%

Receivables

₹6,059 cr9%

Cash & equivalents

₹2,204 cr3%

Other assets

₹34,214 cr52%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Biocon Ltd.	59,497	365.10	131.6	1.71	1.3%

StoxGud checklist: Bearish setup · 3/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+1.4%

6 months-4.5%

1 year-2.3%

3Y CAGR+17.5%

5Y CAGR+0.9%

10Y CAGR+9.3%

50-day avg₹370.92

200-day avg₹390.20

RSI (14)59

Long-term financials (FY12–FY16)

from published annual reports

Year	Revenue	Profit before tax	Net profit
FY16	₹3,485 Cr	₹652 Cr	₹74 Cr
FY15	₹3,090 Cr	₹519 Cr	₹31 Cr
FY14	₹2,877 Cr	₹538 Cr	₹431 Cr
FY13	₹2,485 Cr	₹408 Cr	₹513 Cr
FY12	₹2,086 Cr	₹392 Cr	₹338 Cr

Years before FY17 follow the older Indian GAAP standard, so they are not exactly comparable with recent years.

Compare Biocon Ltd. with

Glenmark Pharmaceuticals vs Biocon Alkem Laboratories vs Biocon Biocon vs Fortis Healthcare Biocon vs Abbott India Biocon vs Gland Pharma

FAQs

What is the share price of Biocon Ltd.?

Biocon Ltd. (BIOCON) closed at ₹365.10 on NSE on 06 Nov 2026.

What is the market cap of Biocon Ltd.?

₹59,497 crore at the latest close.

What is the P/E ratio of Biocon Ltd.?

131.6, on trailing-twelve-month earnings from its filings.

How fast is Biocon Ltd. growing?

Biocon Ltd.: revenue has compounded at 14.8% a year over three years; net profit at -5.9% a year. Latest-quarter revenue is up 2.2% year on year, profit down 51.1%.

How profitable is Biocon Ltd.?

On a trailing-twelve-month basis return on equity is 1.3%, return on capital employed 2.5%, operating margin 20.3%, net margin 2.6%.

How much debt does Biocon Ltd. have?

Biocon Ltd. is lightly geared: debt to equity is 0.43 with borrowings of ₹15,110 cr against cash of ₹2,204 cr (balance sheet of 2026-09-30). Operating profit covers interest 1.4 times.

Financials parsed from Biocon Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from SEP '18, annual from FY19, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.